Andra AP fonden lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 120.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,200 shares of the biopharmaceutical company’s stock after purchasing an additional 1,200 shares during the period. Andra AP fonden’s holdings in Regeneron Pharmaceuticals were worth $984,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the company. Everence Capital Management Inc. increased its stake in shares of Regeneron Pharmaceuticals by 41.6% during the 3rd quarter. Everence Capital Management Inc. now owns 1,737 shares of the biopharmaceutical company’s stock worth $777,000 after purchasing an additional 510 shares in the last quarter. Canada Pension Plan Investment Board increased its stake in shares of Regeneron Pharmaceuticals by 64.2% during the 3rd quarter. Canada Pension Plan Investment Board now owns 36,175 shares of the biopharmaceutical company’s stock worth $16,175,000 after purchasing an additional 14,147 shares in the last quarter. North Point Portfolio Managers Corp OH increased its stake in shares of Regeneron Pharmaceuticals by 1.0% during the 3rd quarter. North Point Portfolio Managers Corp OH now owns 30,306 shares of the biopharmaceutical company’s stock worth $13,550,000 after purchasing an additional 306 shares in the last quarter. Westpac Banking Corp increased its stake in shares of Regeneron Pharmaceuticals by 226.9% during the 3rd quarter. Westpac Banking Corp now owns 16,956 shares of the biopharmaceutical company’s stock worth $7,581,000 after purchasing an additional 11,769 shares in the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its stake in shares of Regeneron Pharmaceuticals by 204.1% during the 3rd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 745 shares of the biopharmaceutical company’s stock worth $333,000 after purchasing an additional 500 shares in the last quarter. 67.80% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) opened at $393.62 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $340.09 and a 1-year high of $543.55. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.63 and a quick ratio of 3.07. The company has a market cap of $43,346.87, a price-to-earnings ratio of 35.03, a price-to-earnings-growth ratio of 1.56 and a beta of 1.56.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, topping analysts’ consensus estimates of $3.83 by $0.16. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The firm had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.45 billion. During the same quarter in the previous year, the business posted $3.13 EPS. The firm’s revenue was up 23.0% compared to the same quarter last year. equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 13.77 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Andra AP fonden Acquires 1,200 Shares of Regeneron Pharmaceuticals, Inc. (REGN)” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://www.watchlistnews.com/andra-ap-fonden-acquires-1200-shares-of-regeneron-pharmaceuticals-inc-regn/1702129.html.

A number of brokerages have recently weighed in on REGN. Royal Bank Of Canada reissued a “sector perform” rating and set a $425.00 price objective (down from $473.00) on shares of Regeneron Pharmaceuticals in a research note on Thursday, November 9th. J P Morgan Chase & Co reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, August 15th. Citigroup Inc. reissued a “buy” rating and set a $480.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday, November 9th. Zacks Investment Research raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $540.00 target price for the company in a research note on Wednesday, August 9th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $580.00 target price (up from $573.00) on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 9th. Three research analysts have rated the stock with a sell rating, fourteen have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $481.49.

In other news, CFO Robert E. Landry sold 189 shares of the business’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $501.06, for a total value of $94,700.34. Following the completion of the sale, the chief financial officer now owns 10,099 shares of the company’s stock, valued at approximately $5,060,204.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Robert E. Landry sold 663 shares of the business’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $498.60, for a total transaction of $330,571.80. Following the completion of the sale, the senior vice president now directly owns 10,099 shares of the company’s stock, valued at approximately $5,035,361.40. The disclosure for this sale can be found here. Insiders sold a total of 88,942 shares of company stock worth $42,064,076 in the last quarter. 10.80% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.